The investigators suggest that the recruited participants may have reached a plateau in symptoms, which may have decreased the chances of additional improvement with belimumab treatment.
Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.
The Myasthenia Gravis Impairment Index was developed to incorporate patient input at different stages of disease progression.
Treatment with eculizumab was associated with a significant benefit on quality of life.
The FDA has approved Soliris for treating adults with myasthenia gravis.
Patients with anti-muscle-specific kinase myasthenia gravis typically have a more severe disease presentation, with early bulbar, neck, and respiratory muscle weakness.
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.
Patients who underwent surgery also experienced lower distress levels from treatment-related symptoms.
The guidelines are the result of a consensus of an international task force of MG experts.
Treatment has been linked to durable, symptom-free, treatment-free remission in several cases of MG.
Neurology Advisor Articles
- Comorbidities in Multiple Sclerosis: Effects on DMTs, the Treatment Team, and More
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- FDA Approves Powerful New Opioid Despite Criticisms
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Efficacy of Naftazone on Motor Symptoms of Parkinson Disease
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- Pediatric Migraine: Evidence-Based Alternative Management
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Circadian, Circaseptan Rhythms Prevalent in Epileptic Seizure Cycles
- Jolt Accentuation of Headache Not a Universal Indicator of Acute Meningitis
- Reduced Survival for Patients With Idiopathic Parkinsonism
- ACA Implementation Decreased Rates of Therapy Nonadherence in Stroke Survivors
- Fluorescence Can ID High-Grade Glioma During Sx for Brain Tumor